key: cord-0817141-r7gg65wg
authors: Hasani, Hamidreza; Hakak-Zargar, Benyamin; Mohammad Poor Nami, Sahar; Mohammadian Khonsari, Nami
title: Bilateral Central Retinal Vein Occlusion and Stevens-Johnson Syndrome Associated with Coronavirus-19: A Case Report
date: 2022-04-16
journal: J Curr Ophthalmol
DOI: 10.4103/joco.joco_277_21
sha: 4d580ae81c3267256ec24e0617d90a4267ef4507
doc_id: 817141
cord_uid: r7gg65wg

PURPOSE: To report a case of bilateral central retinal vein occlusion (CRVO) associated with coronavirus-19 (COVID-19) infection. METHODS: A 43-year-old man presented to the emergency department with flu-like symptoms, severe erythema, a rash on his face, and respiratory distress. He was admitted to the intensive care unit, and the reverse transcriptase-polymerase chain reaction test was positive for the severe acute respiratory syndrome coronavirus-2 virus. The routine blood work was unremarkable. The dermatologist noted positive Nikolsky's sign, and the patient was diagnosed with Stevens–Johnson syndrome (SJS), which affected 18% of his body and was later confirmed by skin biopsy. Later, he reported worsening vision. RESULTS: Ophthalmic examination and fundus fluorescein angiography showed bilateral CRVO. Despite best medical efforts, including treatment with systemic dexamethasone and remdesivir, the patient died on the 6 days of his hospitalization. CONCLUSION: This was a rare bilateral CRVO and SJS case in a young patient, probably caused by the COVID-19 infection.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com distress, with an oxygen saturation of 84% measured with a pulse oximeter. A reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to detect the presence of COVID-19 infection. The PCR was positive for COVID-19, which explained all of his symptoms except the erythema and rash that began three to 4 days after his first flu-like symptoms.

He also stated that 2 days before his admission, he had noticed nonpruritic facial lesions that had gradually worsened.

Physical examination revealed blisters in the fingers, mouth, and genital area. He had no significant medical history and was not using any medications or herbal remedies. The routine laboratory workup was unremarkable. He had a platelet count of 140,000 with otherwise normal complete blood count (CBC), normal serum electrolytes, partial thromboplastin time (PTT), prothrombin time (PT), and international normalized ratio (INR). No signs of lymphopenia and leukocytosis were seen. As a routine, we checked the erythrocyte sedimentation rate, C-reactive protein, and D-dimer levels, which were 87 mm/h, 80 mg/dL, and 2.14 µg/ml, respectively (normal ranges, 0-22 mm/h, 0.8-1 mg/dL, and under 0.5 µg/ml, respectively).

A peripheral blood smear was ordered, which showed no signs of schistocytes or hemolysis. Furthermore, a blood culture (BC) was ordered, which was negative; however, before the BC results, only intravenous azithromycin 500 mg per day was administered. No other antibiotics were given since we suspected that the patient had SJS. The patient's dermatologic lesions were treated with corticosteroid ointments. Vitamin A ointment was administered daily under the patient's eyelids to prevent scarring due to suspicion of SJS.

A dermatologist consultation was requested on the 2 nd day of his admission. The consultation revealed a positive Nikolsky's sign, and the patient was diagnosed with SJS, which affected 18% of his body, based on the dermatologist's evaluation. A skin biopsy later confirmed the diagnosis. Figure 1 demonstrates the appearance of skin lesions. We administered intravenous dexamethasone 8 mg twice daily, remdesivir 200 mg infusion for 1 day, and remdesivir 100 mg infusion for 5 days. To treat SJS, intravenous immunoglobulin with a dosage of 1 gram per kilogram of body weight per day began. His visual acuity on both eyes had dramatically declined relative to baseline on the 2 days of his admission. He stated that the problem began abruptly, and he had no similar experiences in the past. In the ophthalmic examination, a diagnosis of CRVO was made and further confirmed on optical coherence tomography [OCT, Figure 2 ]. Additional laboratory workup for antiphospholipid antibodies (cardiolipin antibodies and β-2 glycoprotein 1 antibodies (immunoglobulin G, immunoglobulin M and immunoglobulin A), and lupus anticoagulant testing) serum fibrinogen and homocysteine levels, antinuclear antibodies (ANA), serum complement (C3 and C4) levels, and the recheck of PT, PTT, and INR were ordered. No abnormalities within antiphospholipid antibody levels and lupus anticoagulant were detected (all immunoglobulins were under 20 U/mg), fibrinogen levels were 290 mg/dL; homocysteine was 11.4 µmol/L, ANA was negative, and C3 and C4 levels were 183 and 49 mg/dL, respectively (both within the normal range).

However, an increase in his PT and PTT levels was detected (PT was 15.5 s and his PTT was 60). We planned to treat the patient's CRVO with intravitreal injections of bevacizumab combined with triamcinolone; however, despite treatment, the patient's condition began to deteriorate. CBC workups on the 5 days of admission revealed a decrease in platelets from 140,000 to 75,000, as well as an increase in creatinine values from 1 to 2.3 mg/dl. Urine analysis revealed hemoglobinuria, and a peripheral blood smear revealed less than 1% schistocytes. Thus, we began plasmapheresis due to suspicions of hemolytic uremic syndrome or thrombotic thrombocytopenic purpura (TTP). However, later lab results ruled out the possibility of TTP based on the normal levels of ADAMTS13 (short for A Disintegrin and Metalloproteinase with Thrombospondin Motifs) protein.

Furthermore, a spiral chest computed tomography revealed a severe COVID-19 infection involving the majority of both lungs. Despite our best efforts, the patient died from COVID-19 cardiopulmonary failure on the 6 days of admission. This case report was approved by the Ethics Committee and Ethics in Research of Alborz University of Medical Sciences. Written consent was obtained from the patient on the 3 days of his admission and from his kin after his death to use his data for research and publication purposes.

COVID-19 infection has been reported to be associated with several ocular diseases. 10 We believe that SJS and bilateral CRVO, in this case, are due to COVID infection, as other possible underlying causes were ruled out. The association between severe COVID-19 and SJS has been reported previously. 11 However, no previous study has identified bilateral CRVO in a patient with COVID-19. Patients with leukemia, multiple myeloma, and other inflammatory systemic disorders may experience CRVO, despite the fact that it is relatively rare, particularly in the younger population. 6, 7, 9 Other causes of CRVO include disseminated intravascular coagulation and TTP, [11] [12] [13] [14] [15] all of which can cause CRVO due to the hypercoagulable state resulting from their inflammation. 5, [11] [12] [13] [14] [15] However, in this case, a viral infection produced a vast inflammatory response that probably predisposed the patient to a state of hypercoagulability, resulting in the aforementioned complications. A thorough follow-up ocular examination was not possible due to the patient's sudden deterioration. Although further evaluations and reports are needed to conclude the exact relationship of COVID-19 with the aforementioned conditions, the severe inflammatory responses arising due to COVID-19 infection and the fact that the infection can cause severe cytokine storm that can result in retinal vasculitis secondary to thromboinflammatory cascades should be considered. 16, 17 

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed.

Nil.

There are no conflicts of interest.

Central retinal vein occlusion: What's the story?

Retinal ischemia: Mechanisms of damage and potential therapeutic strategies

Central retinal vein occlusion: A review

Central retinal vein occlusion in young adults

Systemic considerations in bilateral central retinal vein occlusion

Simultaneous bilateral central retinal vein occlusion associated with anticardiolipin antibodies in leukemia

Bilateral central retinal vein occlusion associated with multiple myeloma

Bilateral central retinal vein occlusion in a patient with scleroderma

Bilateral central retinal vein occlusion caused by malignant hypertension in a young patient

Ocular findings in COVID-19 patients: A review of direct manifestations and indirect effects on the eye

Two false negative test results in a symptomatic patient with a confirmed case of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and suspected Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)

Central retinal vein occlusion in a patient with thrombotic thrombocytopenic purpura

Central retinal vein occlusion associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Complete resolution is possible

Bilateral combined occlusion of the central retinal artery and vein secondary to thrombotic thrombocytopenic purpura

Bilateral central retinal vein occlusion in patient with disseminated intravascular coagulation

Retinal vein occlusion in COVID-19: A novel entity

The cytokine storm and COVID-19